About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...
Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned ...
Technology moves fast, and there’s no better example than the rapid growth of artificial intelligence (AI). Here at Pfizer, we have long been focused on making breakthroughs that change patients’ ...
Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer ...
Pfizer will publish full proposals of funded initiatives, in addition to any milestone updates, interim reports, final outcomes assessments and any other relevant, pertinent data and information that ...
Pfizer Digital continuously seeks opportunities to bring fresh and innovative ideas to our business. The Digital Rotational Program is looking for recent college graduates to join our fast-paced ...
Full-Year 2024 Revenue Guidance (1) Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition Anticipates Approximately $8 Billion in Revenues for Comirnaty (2) and ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) (“Pfizer”) today announced that its wholly owned subsidiary, Pfizer Investment Enterprises Pte. Ltd. (the “Issuer”), has commenced a multi-series ...
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational ...
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older The KP.2 adaptation is based on FDA ...
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community NEW YORK--(BUSINESS WIRE)-- Pfizer Inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results